Moxifloxacin
Injection

freeflex®

Fresenius Kabi has a growing portfolio of premix medications in **free***flex*® bags. All **free***flex* bags are designed with the clinician in mind, to help reduce infusion errors, injury and waste so they can focus on patient care.



Product Code	NDC Code	Strength
850174	63323-850-74	400 mg per 250 mL

Concentration	Fill Size (mL)	Container Size	Units per Case
1.6 mg per mL	250 mL	300 mL	12

- Preservative free
- Non-PVC and Non-DEHP
- The container closure is not made with natural rubber latex

WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS

See full prescribing information for complete boxed warning

- **Fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together including:**
  - **Tendinitis and tendon rupture**
  - **Peripheral neuropathy**
  - **Central nervous system effects**

Discontinue moxifloxacin injection immediately and avoid the use of fluoroquinolones, including moxifloxacin, in patients who experience any of these serious adverse reactions.

- **Fluoroquinolones, including moxifloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid moxifloxacin in patients with known history of myasthenia gravis.**
- **Because fluoroquinolones, including moxifloxacin, have been associated with serious adverse reactions, reserve moxifloxacin for use in patients who have no alternative treatment options for the following indications:**
  - **Acute bacterial sinusitis**
  - **Acute bacterial exacerbation of chronic bronchitis**

Please see Important Safety Information on the following page.

For more information or to place an order, contact your Sales Representative or call Customer Service at 1.888.386.1300 | freeflexivbags.com

FRESENIUS KABI
caring for life

Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, IL 60047
Phone: 1.888.386.1300
www.fresenius-kabi.com/us

2055-MOX-02-08/21

INDICATIONS AND USAGE

Moxifloxacin injection is a fluoroquinolone antibacterial drug indicated for treating infections in adults ≥ 18 years of age caused by designated, susceptible bacteria: community acquired pneumonia, uncomplicated and complicated skin and skin structure infections, complicated intra-abdominal infections, acute bacterial sinusitis, and acute bacterial exacerbation of chronic bronchitis.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS

See full prescribing information for complete boxed warning

- **Fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together including:**
  - **Tendinitis and tendon rupture**
  - **Peripheral neuropathy**
  - **Central nervous system effects**

Discontinue moxifloxacin injection immediately and avoid the use of fluoroquinolones, including moxifloxacin, in patients who experience any of these serious adverse reactions.

- **Fluoroquinolones, including moxifloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid moxifloxacin in patients with known history of myasthenia gravis.**
- **Because fluoroquinolones, including moxifloxacin, have been associated with serious adverse reactions, reserve moxifloxacin for use in patients who have no alternative treatment options for the following indications:**
  - **Acute bacterial sinusitis**
  - **Acute bacterial exacerbation of chronic bronchitis**

Moxifloxacin injection is contraindicated in patients with known hypersensitivity to moxifloxacin or other quinolones.

Prolongation of the QT interval and isolated cases of torsades de pointes have been reported. Avoid use in patients with known prolongation, hypokalemia, and with drugs that prolong the QT interval. Use caution in patients with proarrhythmic conditions such as clinically significant bradycardia or acute myocardial ischemia.

Serious and sometimes fatal hypersensitivity reactions, including anaphylactic reactions, may occur after first or subsequent doses. Discontinue moxifloxacin at the first sign of skin rash, jaundice or any other sign of hypersensitivity.

Clostridium difficile-associated diarrhea: evaluate if diarrhea occurs.

High sodium load: Each unit dose contains 52.5 mEq (1,207 mg) of sodium. Avoid in patients with sodium restriction.

The most common adverse reactions (≥ 3%) were nausea, diarrhea, headache, and dizziness.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions:

Interacting Drug	Interaction
Warfarin	Anticoagulant effect of warfarin may be enhanced. Monitor prothrombin time/INR, watch for bleeding.
Class IA and Class III antiarrhythmics:	Proarrhythmic effect may be enhanced. Avoid concomitant use.
Antidiabetic agents	Carefully monitor blood glucose.

Pregnancy: Based on animal data may case fetal harm.

Geriatrics: Increased risk for severe tendon disorders further increased by concomitant corticosteroid therapy and increased risk of prolongation of the QT interval.

This Important Safety Information does not include all the information needed to use Moxifloxacin Injection safely and effectively. Please see full prescribing information for MOXIFLOXACIN INJECTION, including BOXED WARNING. Full prescribing information is available at www.fresenius-kabi.com/us.

FRESENIUS KABI
caring for life

Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, IL 60047
Phone: 1.888.386.1300
www.fresenius-kabi.com/us

2055-MOX-02-08/21